Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicent
Research payments
$130,281
Through program year 2019, $130,281 in research payments was reported against Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicent, across 15 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $130,281 | 15 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Roger Abrahams Morgantown, WV Named on 2 payments
- James Wells Birmingham, AL Named on 2 payments
- Gregory Feldman Spartanburg, SC Named on 2 payments
- Edward Kerwin Medford, OR Named on 2 payments
- Alan Thomas Birmingham, AL Named on 2 payments
- Murali Ramaswamy Greensboro, NC Named on 2 payments
- Shawn Magee Topeka, KS Named on 1 payment
- Thomas Hyers Saint Louis, MO Named on 1 payment
- Richard Sterling Orangeburg, SC Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.